Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 229 articles: HTML format

Single Articles

April 2024
1. RIOS-HOYO A, Cobain E, Huppert LA, Beitsch PD, et al
   Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
   J Clin Oncol. 2024 Apr 9:JCO2302614. doi: 10.1200/JCO.23.02614.
   PubMed    
   
   
   
2. VALENZA C, Trapani D, Loibl S, Chia SKL, et al
   Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.
   J Clin Oncol. 2024 Apr 3:JCO2301935. doi: 10.1200/JCO.23.01935.
   PubMed     Abstract available
   
   
   
3. MUTTER RW, Chauhan C, Goetz MP, Wright JL, et al
   Revisiting Combined Modality Therapy in Older Patients With Luminal Breast Cancer Through the Patient Lens.
   J Clin Oncol. 2024 Apr 2:JCO2302289. doi: 10.1200/JCO.23.02289.
   PubMed    
   
   
   March 2024
4. MARTIN M, Lim E, Chavez-MacGregor M, Bardia A, et al
   Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
   J Clin Oncol. 2024 Mar 27:JCO2301500. doi: 10.1200/JCO.23.01500.
   PubMed     Abstract available
   
   
   
5. MAYER EL, Ren Y, Wagle N, Mahtani R, et al
   PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Bre
   J Clin Oncol. 2024 Mar 21:JCO2301940. doi: 10.1200/JCO.23.01940.
   PubMed     Abstract available
   
   
   
6. SALTBAEK L, Bidstrup PE, Karlsen RV, Hoeg BL, et al
   Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial.
   J Clin Oncol. 2024 Mar 18:JCO2301447. doi: 10.1200/JCO.23.01447.
   PubMed     Abstract available
   
   
   
7. MANN GB, Rose AK, Zdenkowski N
   What About This IDEA: The PROSPECT That Occult Malignant Lesions May Explain Local Recurrences in Very Early Breast Cancer?
   J Clin Oncol. 2024 Mar 15:JCO2302729. doi: 10.1200/JCO.23.02729.
   PubMed    
   
   
   
8. BURSTEIN HJ, DeMichele A, Fallowfield L, Somerfield MR, et al
   Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
   J Clin Oncol. 2024 Mar 13:JCO2400248. doi: 10.1200/JCO.24.00248.
   PubMed     Abstract available
   
   
   
9. RADFORD J
   Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers.
   J Clin Oncol. 2024 Mar 13:JCO2302763. doi: 10.1200/JCO.23.02763.
   PubMed    
   
   
   February 2024
10. MARS N, Kerminen S, Tamlander M, Pirinen M, et al
    Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.
    J Clin Oncol. 2024 Feb 29:JCO2300295. doi: 10.1200/JCO.23.00295.
    PubMed     Abstract available
    
    
    
11. BARDIA A, Rugo HS, Tolaney SM, Loirat D, et al
    Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
    J Clin Oncol. 2024 Feb 29:JCO2301409. doi: 10.1200/JCO.23.01409.
    PubMed     Abstract available
    
    
    
12. MAXWELL KN, Domchek SM
    Toward Application of Polygenic Risk Scores to Both Enhance and Deintensify Breast Cancer Screening.
    J Clin Oncol. 2024 Feb 29:JCO2400029. doi: 10.1200/JCO.24.00029.
    PubMed    
    
    
    
13. 
    Erratum: Pathologic Exploration of the Axillary Soft Tissue Microenvironment and Its Impact on Axillary Management and Breast Cancer Outcomes.
    J Clin Oncol. 2024 Feb 23:JCO2400317. doi: 10.1200/JCO.24.00317.
    PubMed    
    
    
    
14. WORIAX HE, Thomas SM, Plichta JK, Rosenberger LH, et al
    Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy.
    J Clin Oncol. 2024 Feb 23:JCO2301199. doi: 10.1200/JCO.23.01199.
    PubMed     Abstract available
    
    
    
15. SHAH M, Lingam H, Gao X, Gittleman H, et al
    US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.
    J Clin Oncol. 2024 Feb 21:JCO2302112. doi: 10.1200/JCO.23.02112.
    PubMed     Abstract available
    
    
    
16. MCGRADY ME, Willard VW, Williams AM, Brinkman TM, et al
    Psychological Outcomes in Adolescent and Young Adult Cancer Survivors.
    J Clin Oncol. 2024;42:707-716.
    PubMed     Abstract available
    
    
    
17. CHEN JC, Elsaid MI, Handley D, Plascak JJ, et al
    Association Between Neighborhood Opportunity, Allostatic Load, and All-Cause Mortality in Patients With Breast Cancer.
    J Clin Oncol. 2024 Feb 16:JCO2300907. doi: 10.1200/JCO.23.00907.
    PubMed     Abstract available
    
    
    
18. NEPPELENBROEK SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, et al
    Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
    J Clin Oncol. 2024 Feb 15:JCO2301386. doi: 10.1200/JCO.23.01386.
    PubMed     Abstract available
    
    
    
19. GEYER CE JR, Blum JL, Yothers G, Asmar L, et al
    Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
    J Clin Oncol. 2024 Feb 9:JCO2301428. doi: 10.1200/JCO.23.01428.
    PubMed     Abstract available
    
    
    
20. GANZ PA, Bandos H, Spanic T, Friedman S, et al
    Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
    J Clin Oncol. 2024 Feb 1:JCO2301214. doi: 10.1200/JCO.23.01214.
    PubMed     Abstract available
    
    
    January 2024
21. 
    Erratum: Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
    J Clin Oncol. 2024 Jan 22:JCO2400028. doi: 10.1200/JCO.24.00028.
    PubMed    
    
    
    
22. SLAMON DJ, Dieras V, Rugo HS, Harbeck N, et al
    Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
    J Clin Oncol. 2024 Jan 22:JCO2300137. doi: 10.1200/JCO.23.00137.
    PubMed     Abstract available
    
    
    
23. ALAEIKHANEHSHIR S, Ajayi T, Duijnhoven FH, Poncet C, et al
    Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature.
    J Clin Oncol. 2024 Jan 19:JCO2202690. doi: 10.1200/JCO.22.02690.
    PubMed     Abstract available
    
    
    
24. RASTOGI P, O'Shaughnessy J, Martin M, Boyle F, et al
    Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficac
    J Clin Oncol. 2024 Jan 9:JCO2301994. doi: 10.1200/JCO.23.01994.
    PubMed     Abstract available
    
    
    
25. MORGANTI S, Gibson CJ, Jin Q, Santos K, et al
    Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.
    J Clin Oncol. 2024 Jan 8:JCO2301071. doi: 10.1200/JCO.23.01071.
    PubMed     Abstract available
    
    
    
26. BEDROSIAN I, Somerfield MR, Achatz MI, Boughey JC, et al
    Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.
    J Clin Oncol. 2024 Jan 4:JCO2302225. doi: 10.1200/JCO.23.02225.
    PubMed     Abstract available
    
    
    
27. MERIC-BERNSTAM F, Makker V, Oaknin A, Oh DY, et al
    Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
    J Clin Oncol. 2024;42:47-58.
    PubMed     Abstract available
    
    
    December 2023
28. 
    Erratum: Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth
    J Clin Oncol. 2023 Dec 19:JCO2302620. doi: 10.1200/JCO.23.02620.
    PubMed    
    
    
    
29. TIMMINS IR, Jones ME, O'Brien KM, Adami HO, et al
    International Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts.
    J Clin Oncol. 2023 Dec 11:JCO2301101. doi: 10.1200/JCO.23.01101.
    PubMed     Abstract available
    
    
    
30. JAGSI R, Griffith KA, Harris EE, Wright JL, et al
    Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA.
    J Clin Oncol. 2023 Dec 7:JCO2302270. doi: 10.1200/JCO.23.02270.
    PubMed     Abstract available
    
    
    
31. BRAUNSTEIN LZ, Khan AJ
    Optimization of Breast Cancer Regional Nodal Management.
    J Clin Oncol. 2023 Dec 4:JCO2302121. doi: 10.1200/JCO.23.02121.
    PubMed    
    
    
    November 2023
32. GARD CC, Tice JA, Miglioretti DL, Sprague BL, et al
    Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer.
    J Clin Oncol. 2023 Nov 17:JCO2202470. doi: 10.1200/JCO.22.02470.
    PubMed     Abstract available
    
    
    
33. NAOUM GE, Oladeru O, Ababneh H, Shui A, et al
    Pathological Exploration of the Axillary Soft Tissue Microenvironment and Its Impact on Axillary Management and Breast Cancer Outcomes.
    J Clin Oncol. 2023 Nov 15:JCO2301009. doi: 10.1200/JCO.23.01009.
    PubMed     Abstract available
    
    
    
34. HIS M, Gunter MJ, Keski-Rahkonen P, Rinaldi S, et al
    Application of Metabolomics to Epidemiologic Studies of Breast Cancer: New Perspectives for Etiology and Prevention.
    J Clin Oncol. 2023 Nov 9:JCO2202754. doi: 10.1200/JCO.22.02754.
    PubMed     Abstract available
    
    
    
35. BIDARD FC, Kiavue N, Jacot W, Bachelot T, et al
    Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.
    J Clin Oncol. 2023 Nov 6:JCO2300456. doi: 10.1200/JCO.23.00456.
    PubMed     Abstract available
    
    
    October 2023
36. YOSHITOMI Y, Shimomura A, Shimizu C
    Oral Selective Estrogen Receptor Degrader for Advanced Breast Cancer.
    J Clin Oncol. 2023 Oct 30:JCO2301656. doi: 10.1200/JCO.23.01656.
    PubMed    
    
    
    
37. ESKREIS-WINKLER S, Sung JS, Dixon L, Monga N, et al
    High-Temporal/High-Spatial Resolution Breast Magnetic Resonance Imaging Improves Diagnostic Accuracy Compared With Standard Breast Magnetic Resonance Imaging in Patients With High Background Parenchymal Enhancement.
    J Clin Oncol. 2023;41:4747-4755.
    PubMed     Abstract available
    
    
    
38. KROP IE, Masuda N, Mukohara T, Takahashi S, et al
    Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II
    J Clin Oncol. 2023 Oct 6:JCO2300882. doi: 10.1200/JCO.23.00882.
    PubMed     Abstract available
    
    
    
39. CAO C, Ligibel JA
    Too Much, Too Little, or Just Right? Obesity and Dosing of Targeted Therapies in Breast Cancer.
    J Clin Oncol. 2023 Oct 5:JCO2301516. doi: 10.1200/JCO.23.01516.
    PubMed    
    
    
    September 2023
40. CONTE P, Bisagni G, Piacentini F, Sarti S, et al
    Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
    J Clin Oncol. 2023 Sep 25:JCO2300790. doi: 10.1200/JCO.23.00790.
    PubMed     Abstract available
    
    
    
41. IM C, Sharafeldin N, Yuan Y, Wang Z, et al
    Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report.
    J Clin Oncol. 2023;41:4381-4393.
    PubMed     Abstract available
    
    
    
42. 
    Erratum: Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer.
    J Clin Oncol. 2023 Sep 12:JCO2301807. doi: 10.1200/JCO.23.01807.
    PubMed    
    
    
    
43. GOODWIN PJ, Chen BE, Gelmon KA, Whelan TJ, et al
    Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
    J Clin Oncol. 2023 Sep 11:JCO2300296. doi: 10.1200/JCO.23.00296.
    PubMed     Abstract available
    
    
    
44. HOE HJ, Solomon BJ
    Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer: A Reminder That More Is Not Always Better.
    J Clin Oncol. 2023 Sep 11:JCO2301768. doi: 10.1200/JCO.23.01768.
    PubMed    
    
    
    
45. PARKER JS, Mullins M, Cheang MCU, Leung S, et al
    Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes.
    J Clin Oncol. 2023;41:4192-4199.
    PubMed     Abstract available
    
    
    
46. 
    JCO Flashback: An Intrinsic Subtype-Based Risk Prediction Model for Early-Stage Breast Cancer (2009).
    J Clin Oncol. 2023;41:4191.
    PubMed    
    
    
    
47. SOLDATO D, Miller KD
    Flashback Foreword: Supervised Risk Predictor of Breast Cancer.
    J Clin Oncol. 2023;41:4189-4190.
    PubMed    
    
    
    
48. SANFT T, Harrigan M, McGowan C, Cartmel B, et al
    Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study.
    J Clin Oncol. 2023 Sep 1:JCO2300871. doi: 10.1200/JCO.23.00871.
    PubMed     Abstract available
    
    
    August 2023
49. PUSZTAI L, Rozenblit M, Dubsky P, Bachelot T, et al
    De Novo Oligometastatic Breast Cancer.
    J Clin Oncol. 2023 Aug 22:JCO2300911. doi: 10.1200/JCO.23.00911.
    PubMed    
    
    
    
50. BAEK SY, Noh WC, Ahn SH, Kim HA, et al
    Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial.
    J Clin Oncol. 2023 Aug 22:JCO2300557. doi: 10.1200/JCO.23.00557.
    PubMed     Abstract available
    
    
    
51. PFEILER G, Hlauschek D, Mayer EL, Deutschmann C, et al
    Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
    J Clin Oncol. 2023 Aug 9:JCO2300126. doi: 10.1200/JCO.23.00126.
    PubMed     Abstract available
    
    
    
52. WILKINSON AN, Ellison LF, Billette JM, Seely JM, et al
    Impact of Breast Cancer Screening on 10-Year Net Survival in Canadian Women Age 40-49 Years.
    J Clin Oncol. 2023 Aug 4:JCO2300348. doi: 10.1200/JCO.23.00348.
    PubMed     Abstract available
    
    
    
53. BRIGHT EE, Finkelstein LB, Nealis MS, Genung SR, et al
    A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors.
    J Clin Oncol. 2023 Aug 2:JCO2300697. doi: 10.1200/JCO.23.00697.
    PubMed     Abstract available
    
    
    July 2023
54. 
    Erratum: Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
    J Clin Oncol. 2023 Jul 14:JCO2301370. doi: 10.1200/JCO.23.01370.
    PubMed    
    
    
    
55. YU KD
    Inconsistent Data Between Distant Relapse Events and Breast Cancer-Specific Death Events in India Lidocaine Trial.
    J Clin Oncol. 2023 Jul 11:JCO2300976. doi: 10.1200/JCO.23.00976.
    PubMed    
    
    
    
56. LITTON JK, Regan MM, Pusztai L, Rugo HS, et al
    Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
    J Clin Oncol. 2023 Jul 11:JCO2300435. doi: 10.1200/JCO.23.00435.
    PubMed     Abstract available
    
    
    
57. PAIK S, Tang G, Shak S, Kim C, et al
    Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2023;41:3565-3575.
    PubMed     Abstract available
    
    
    
58. WOLFF AC
    Flashback Foreword: Multigene Predictor for Chemotherapy Response in Breast Cancer.
    J Clin Oncol. 2023;41:3563-3564.
    PubMed    
    
    
    
59. JACKSON EB, Chia SKL
    Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
    J Clin Oncol. 2023 Jul 5:JCO2300759. doi: 10.1200/JCO.23.00759.
    PubMed     Abstract available
    
    
    June 2023
60. 
    Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD
    J Clin Oncol. 2023 Jun 26:JCO2301239. doi: 10.1200/JCO.23.01239.
    PubMed    
    
    
    
61. 
    Erratum: Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
    J Clin Oncol. 2023 Jun 26:JCO2301230. doi: 10.1200/JCO.23.01230.
    PubMed    
    
    
    
62. PUSZTAI L
    Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look?
    J Clin Oncol. 2023 Jun 22:JCO2300977. doi: 10.1200/JCO.23.00977.
    PubMed    
    
    
    
63. TOLANEY SM, Chan A, Petrakova K, Delaloge S, et al
    AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
    J Clin Oncol. 2023 Jun 22:JCO2202746. doi: 10.1200/JCO.22.02746.
    PubMed     Abstract available
    
    
    
64. LAZZERONI M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, et al
    Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
    J Clin Oncol. 2023;41:3116-3121.
    PubMed     Abstract available
    
    
    
65. WOLFF AC, Somerfield MR, Dowsett M, Hammond MEH, et al
    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.
    J Clin Oncol. 2023 Jun 7:JCO2202864. doi: 10.1200/JCO.22.02864.
    PubMed     Abstract available
    
    
    
66. WANG Y, Cai Q
    Could Adjuvant Radiotherapy Be Avoided for Postmenopausal Patients With Node-Positive Estrogen Receptor-Positive Breast Cancer and Favorable Recurrence Score and SET2,3 Scores?
    J Clin Oncol. 2023 Jun 1:JCO2300210. doi: 10.1200/JCO.23.00210.
    PubMed    
    
    
    May 2023
67. DAYES IS, Metser U, Hodgson N, Parpia S, et al
    Impact of (18)F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer.
    J Clin Oncol. 2023 May 26:JCO2300249. doi: 10.1200/JCO.23.00249.
    PubMed     Abstract available
    
    
    
68. KINNEY AY, Walters ST, Lin Y, Lu SE, et al
    Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    J Clin Oncol. 2023;41:2767-2778.
    PubMed     Abstract available
    
    
    
69. KALINSKY K, Accordino MK, Chiuzan C, Mundi PS, et al
    Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Tr
    J Clin Oncol. 2023 May 19:JCO2202392. doi: 10.1200/JCO.22.02392.
    PubMed     Abstract available
    
    
    
70. BURSTEIN HJ, DeMichele A, Somerfield MR, Henry NL, et al
    Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2023 May 17:JCO2300638. doi: 10.1200/JCO.23.00638.
    PubMed     Abstract available
    
    
    
71. 
    Erratum: Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
    J Clin Oncol. 2023 May 10:JCO2300870. doi: 10.1200/JCO.23.00870.
    PubMed    
    
    
    
72. LAWS A, Punglia RS
    Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer.
    J Clin Oncol. 2023 May 1:JCO2300455. doi: 10.1200/JCO.23.00455.
    PubMed     Abstract available
    
    
    
73. BERG WA, Zuley ML, Chang TS, Gizienski TA, et al
    Prospective Multicenter Diagnostic Performance of Technologist-Performed Screening Breast Ultrasound After Tomosynthesis in Women With Dense Breasts (the DBTUST).
    J Clin Oncol. 2023;41:2403-2415.
    PubMed     Abstract available
    
    
    April 2023
74. ROYCE M, Mulkey F, Osgood C, Bloomquist E, et al
    US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer.
    J Clin Oncol. 2023 Apr 27:JCO2300615. doi: 10.1200/JCO.23.00615.
    PubMed    
    
    
    
75. VACHON CM, Scott CG, Norman AD, Khanani SA, et al
    Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer.
    J Clin Oncol. 2023 Apr 27:JCO2201153. doi: 10.1200/JCO.22.01153.
    PubMed     Abstract available
    
    
    
76. IWASE T, Saji S, Iijima K, Higaki K, et al
    Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
    J Clin Oncol. 2023 Apr 20:JCO2200577. doi: 10.1200/JCO.22.00577.
    PubMed     Abstract available
    
    
    
77. ESSERMAN LJ, Ali H, McKenzie T
    When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.
    J Clin Oncol. 2023;41:2144-2150.
    PubMed     Abstract available
    
    
    
78. MEDURI B, Baldissera A, Iotti C, Scheijmans LJEE, et al
    Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial.
    J Clin Oncol. 2023;41:2201-2210.
    PubMed     Abstract available
    
    
    
79. VAN MACKELENBERGH MT, Loibl S, Untch M, Buyse M, et al
    Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
    J Clin Oncol. 2023 Apr 19:JCO2202241. doi: 10.1200/JCO.22.02241.
    PubMed     Abstract available
    
    
    
80. ZHAO YF, Du JX, Zhu W
    A Brand New BRCA-CRisk Model Precisely Predicts the Prognosis of Patients With Breast Cancer and BRCA1/2 Mutation.
    J Clin Oncol. 2023 Apr 11:JCO2202893. doi: 10.1200/JCO.22.02893.
    PubMed    
    
    
    
81. HIGGINS T, Mittendorf EA
    Peritumoral Lidocaine Injection: A Low-Cost, Easily Implemented Intervention to Improve Outcomes in Early-Stage Breast Cancer.
    J Clin Oncol. 2023 Apr 6:JCO2300418. doi: 10.1200/JCO.23.00418.
    PubMed    
    
    
    
82. BADWE RA, Parmar V, Nair N, Joshi S, et al
    Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer.
    J Clin Oncol. 2023 Apr 6:JCO2201966. doi: 10.1200/JCO.22.01966.
    PubMed     Abstract available
    
    
    
83. FISHER B, Bryant J, Wolmark N, Mamounas E, et al
    Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
    J Clin Oncol. 2023;41:1795-1808.
    PubMed     Abstract available
    
    
    
84. LIEDTKE C, Mazouni C, Hess KR, Andre F, et al
    Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.
    J Clin Oncol. 2023;41:1809-1815.
    PubMed     Abstract available
    
    
    
85. HUDIS CA
    Flashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast Cancer.
    J Clin Oncol. 2023;41:1793-1794.
    PubMed    
    
    
    
86. SPEERS CW, Symmans WF, Barlow WE, Trevarton A, et al
    Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.
    J Clin Oncol. 2023;41:1841-1848.
    PubMed     Abstract available
    
    
    
87. JI X, Shi KS, Mertens AC, Zhao J, et al
    Survival in Young Adults With Cancer Is Associated With Medicaid Expansion Through the Affordable Care Act.
    J Clin Oncol. 2023;41:1909-1920.
    PubMed     Abstract available
    
    
    March 2023
88. BOUGHEY JC, Rosenkranz KM, Ballman KV, McCall L, et al
    Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance).
    J Clin Oncol. 2023 Mar 28:JCO2202553. doi: 10.1200/JCO.22.02553.
    PubMed     Abstract available
    
    
    
89. SQUIFFLET P, Saad ED, Loibl S, van Mackelenbergh MT, et al
    Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Re
    J Clin Oncol. 2023 Mar 28:JCO2202363. doi: 10.1200/JCO.22.02363.
    PubMed     Abstract available
    
    
    
90. PLICHTA JK, Thomas SM, Hayes DF, Chavez-MacGregor M, et al
    Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer.
    J Clin Oncol. 2023 Mar 21:JCO2202222. doi: 10.1200/JCO.22.02222.
    PubMed     Abstract available
    
    
    
91. VOGEL CL, Cobleigh MA, Tripathy D, Gutheil JC, et al
    Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
    J Clin Oncol. 2023;41:1638-1645.
    PubMed     Abstract available
    
    
    
92. 
    JCO Flashback: Trastuzumab Monotherapy for HER2-Positive Breast Cancer (2002).
    J Clin Oncol. 2023;41:1637.
    PubMed    
    
    
    
93. GRIGGS JJ
    Flashback Foreword: Activity of First-Line Trastuzumab.
    J Clin Oncol. 2023;41:1635-1636.
    PubMed    
    
    
    
94. ERIKSSON M, Czene K, Vachon C, Conant EF, et al
    Long-Term Performance of an Image-Based Short-Term Risk Model for Breast Cancer.
    J Clin Oncol. 2023 Mar 17:JCO2201564. doi: 10.1200/JCO.22.01564.
    PubMed     Abstract available
    
    
    
95. COBLEIGH MA, Vogel CL, Tripathy D, Robert NJ, et al
    Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
    J Clin Oncol. 2023;41:1501-1510.
    PubMed     Abstract available
    
    
    
96. HARVEY JM, Clark GM, Osborne CK, Allred DC, et al
    Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer.
    J Clin Oncol. 2023;41:1331-1338.
    PubMed     Abstract available
    
    
    
97. GANZ PA
    Flashback Foreword: Estrogen Receptor by Immunohistochemistry in Breast Cancer.
    J Clin Oncol. 2023;41:1329-1330.
    PubMed    
    
    
    February 2023
98. HARBECK N, Nitz UA, Christgen M, Kummel S, et al
    De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
    J Clin Oncol. 2023 Feb 21:JCO2201816. doi: 10.1200/JCO.22.01816.
    PubMed     Abstract available
    
    
    
99. NARAYAN P, Dilawari A, Osgood C, Feng Z, et al
    US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
    J Clin Oncol. 2023 Feb 13:JCO2202447. doi: 10.1200/JCO.22.02447.
    PubMed     Abstract available
    
    
    
100. YANG S, Tan M, Gao F, Xu X, et al
     Cognitive Problems in Older Breast Cancer Survivors.
     J Clin Oncol. 2023 Feb 13:JCO2202282. doi: 10.1200/JCO.22.02282.
     PubMed    
     
     
     January 2023
101. TAGLIAMENTO M, Gennari A, Lambertini M, Salazar R, et al
     Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer.
     J Clin Oncol. 2023 Jan 31:JCO2201667. doi: 10.1200/JCO.22.01667.
     PubMed     Abstract available
     
     
     
102. TRAPANI D
     Adjuvant Chemotherapy in Older Women With Early Breast Cancer.
     J Clin Oncol. 2023 Jan 30:JCO2202477. doi: 10.1200/JCO.22.02477.
     PubMed     Abstract available
     
     
     
103. LEVASSEUR N, Gelmon KA
     Prognostic Tests in Early-Stage Hormone Receptor-Positive Breast Cancer: An Opportunity to Refine Personalized Cancer Care.
     J Clin Oncol. 2023 Jan 26:JCO2202863. doi: 10.1200/JCO.22.02863.
     PubMed    
     
     
     
104. LOPES CARDOZO JMN, Andrulis IL, Bojesen SE, Dork T, et al
     Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.
     J Clin Oncol. 2023 Jan 23:JCO2201978. doi: 10.1200/JCO.22.01978.
     PubMed     Abstract available
     
     
     
105. HERSHMAN DL, Bansal A, Sullivan SD, Barlow WE, et al
     A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia.
     J Clin Oncol. 2023;41:590-598.
     PubMed     Abstract available
     
     
     
106. KONSTANTINOPOULOS PA, Lee EK, Xiong N, Krasner C, et al
     A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
     J Clin Oncol. 2023;41:599-608.
     PubMed     Abstract available
     
     
     
107. MOY B, Rumble RB, Carey LA
     Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
     J Clin Oncol. 2023 Jan 10:JCO2202807. doi: 10.1200/JCO.22.02807.
     PubMed     Abstract available
     
     
     
108. YADAV S, Boddicker NJ, Na J, Polley EC, et al
     Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
     J Clin Oncol. 2023 Jan 9:JCO2201239. doi: 10.1200/JCO.22.01239.
     PubMed     Abstract available
     
     
     
109. SG N, Gogia A
     Sacituzumab Govitecan in Hormone Receptor-Positive Metastatic Breast Cancer.
     J Clin Oncol. 2023 Jan 6:JCO2202113. doi: 10.1200/JCO.22.02113.
     PubMed    
     
     
     
110. NATTINGER AB, Bickell NA, Schymura MJ, Laud P, et al
     Centralization of Initial Care and Improved Survival of Poor Patients With Breast Cancer.
     J Clin Oncol. 2023 Jan 5:JCO2202012. doi: 10.1200/JCO.22.02012.
     PubMed     Abstract available
     
     
     
111. SJOSTROM M, Fyles A, Liu FF, McCready D, et al
     Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
     J Clin Oncol. 2023 Jan 4:JCO2200655. doi: 10.1200/JCO.22.00655.
     PubMed     Abstract available
     
     
     December 2022
112. NAOUM GE, Taghian AG
     Endocrine Treatment for 5 Years or Radiation for 5 Days for Patients With Early Breast Cancer Older Than 65 Years: Can We Do It Right?
     J Clin Oncol. 2022 Dec 20:JCO2202171. doi: 10.1200/JCO.22.02171.
     PubMed    
     
     
     
113. NISHIHARA R, Shimomura A, Shimizu C
     Oral Selective Estrogen Receptor Degrader After Endocrine Therapy With a Cyclin-Dependent Kinase 4/6 Inhibitor.
     J Clin Oncol. 2022;40:4280-4281.
     PubMed    
     
     
     
114. CONNOLLY RM, Miller KD
     Back to the Beginning: The Role of Ovarian Suppression in Management of Hormone Sensitive Breast Cancer in Premenopausal Women.
     J Clin Oncol. 2022 Dec 15:JCO2202319. doi: 10.1200/JCO.22.02319.
     PubMed    
     
     
     
115. PAGANI O, Walley BA, Fleming GF, Colleoni M, et al
     Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
     J Clin Oncol. 2022 Dec 15:JCO2201064. doi: 10.1200/JCO.22.01064.
     PubMed     Abstract available
     
     
     
116. FRANCIS PA, Fleming GF, Lang I, Ciruelos EM, et al
     Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
     J Clin Oncol. 2022 Dec 9:JCO2201065. doi: 10.1200/JCO.22.01065.
     PubMed     Abstract available
     
     
     
117. BEHROOZIAN T, Milton L, Karam I, Zhang L, et al
     Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial.
     J Clin Oncol. 2022 Dec 9:JCO2201873. doi: 10.1200/JCO.22.01873.
     PubMed     Abstract available
     
     
     
118. SUN J, Chu F, Pan J, Zhang Y, et al
     BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers.
     J Clin Oncol. 2022 Dec 8:JCO2200833. doi: 10.1200/JCO.22.00833.
     PubMed     Abstract available
     
     
     
119. SEDRAK MS, Sun CL, Ji J, Cohen HJ, et al
     Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial.
     J Clin Oncol. 2022 Dec 1:JCO2201440. doi: 10.1200/JCO.22.01440.
     PubMed     Abstract available
     
     
     
120. JAYASEKERA J, Zhao A, Schechter C, Lowry K, et al
     Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.
     J Clin Oncol. 2022 Dec 1:JCO2201342. doi: 10.1200/JCO.22.01342.
     PubMed     Abstract available
     
     
     November 2022
121. SANTA-MARIA CA, Wolff AC
     Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets.
     J Clin Oncol. 2022 Nov 29:JCO2202217. doi: 10.1200/JCO.22.02217.
     PubMed    
     
     
     
122. BARTELS SAL, Donker M, Poncet C, Sauve N, et al
     Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.
     J Clin Oncol. 2022 Nov 16:JCO2201565. doi: 10.1200/JCO.22.01565.
     PubMed     Abstract available
     
     
     
123. HOFHEINZ RD, Merx K, Haag GM, Springfeld C, et al
     FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
     J Clin Oncol. 2022;40:3750-3761.
     PubMed     Abstract available
     
     
     
124. RUGO HS, Im SA, Cardoso F, Cortes J, et al
     Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
     J Clin Oncol. 2022 Nov 4:JCO2102937. doi: 10.1200/JCO.21.02937.
     PubMed     Abstract available
     
     
     
125. MORAN MS, Ho AY
     Radiation Therapy for Low-Risk Breast Cancer: Whole, Partial, or None?
     J Clin Oncol. 2022 Nov 4:JCO2201751. doi: 10.1200/JCO.22.01751.
     PubMed     Abstract available
     
     
     
126. MCCAW ZR, Ludmir EB, Wei LJ
     Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
     J Clin Oncol. 2022 Nov 3:JCO2201759. doi: 10.1200/JCO.22.01759.
     PubMed    
     
     
     
127. AKECHI T, Yamaguchi T, Uchida M, Imai F, et al
     Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study).
     J Clin Oncol. 2022 Nov 2:JCO2200699. doi: 10.1200/JCO.22.00699.
     PubMed     Abstract available
     
     
     
128. HINDIE E, Groheux D
     Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help.
     J Clin Oncol. 2022;40:3669-3670.
     PubMed    
     
     
     
129. GAIL MH, Jatoi I
     Tools for Contralateral Prophylactic Mastectomy Decision Making.
     J Clin Oncol. 2022;40:3653-3659.
     PubMed     Abstract available
     
     
     October 2022
130. EVRON E, Ben-David MA, Kaidar-Person O, Corn BW, et al
     Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
     J Clin Oncol. 2022 Oct 28:JCO2201609. doi: 10.1200/JCO.22.01609.
     PubMed    
     
     
     
131. WONG FL, Lee JM, Leisenring WM, Neglia JP, et al
     Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
     J Clin Oncol. 2022 Oct 20:JCO2200574. doi: 10.1200/JCO.22.00574.
     PubMed     Abstract available
     
     
     
132. SANCHEZ KG, Nangia JR, Schiff R, Rimawi MF, et al
     Elacestrant and the Promise of Oral SERDs.
     J Clin Oncol. 2022;40:3227-3229.
     PubMed    
     
     
     September 2022
133. CARROLL JE, Nakamura ZM, Small BJ, Zhou X, et al
     Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.
     J Clin Oncol. 2022 Sep 30:JCO2200406. doi: 10.1200/JCO.22.00406.
     PubMed     Abstract available
     
     
     
134. JI J, Sun CL, Cohen HJ, Synold T, et al
     Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study.
     J Clin Oncol. 2022 Sep 20:JCO2201217. doi: 10.1200/JCO.22.01217.
     PubMed     Abstract available
     
     
     
135. LV M, Luo X, Chen Y
     Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology.
     J Clin Oncol. 2022 Sep 19:JCO2201061. doi: 10.1200/JCO.22.01061.
     PubMed    
     
     
     
136. WHEELER SB, Rotter J, Gogate A, Reeder-Hayes KE, et al
     Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.
     J Clin Oncol. 2022 Sep 2:JCO2102473. doi: 10.1200/JCO.21.02473.
     PubMed     Abstract available
     
     
     August 2022
137. MANKOFF DA, Clark AS, Edmonds CE, O'Brien SR, et al
     16alpha-[(18)F]Fluoro-17beta-Estradiol Positron Emission Tomography to Measure Regional Estrogen Receptor Expression in Breast Cancer.
     J Clin Oncol. 2022 Aug 30:JCO2201055. doi: 10.1200/JCO.22.01055.
     PubMed    
     
     
     
138. RUGO HS, Bardia A, Marme F, Cortes J, et al
     Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
     J Clin Oncol. 2022 Aug 26:JCO2201002. doi: 10.1200/JCO.22.01002.
     PubMed     Abstract available
     
     
     
139. DAVIDSON NE
     In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer.
     J Clin Oncol. 2022 Aug 26:JCO2201465. doi: 10.1200/JCO.22.01465.
     PubMed    
     
     
     
140. OFFERSEN BV, Alsner J, Nielsen HM, Jakobsen EH, et al
     Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial.
     J Clin Oncol. 2022 Aug 5:JCO2200451. doi: 10.1200/JCO.22.00451.
     PubMed     Abstract available
     
     
     
141. MOY B, Rumble RB, Carey LA
     Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
     J Clin Oncol. 2022 Aug 4:JCO2201533. doi: 10.1200/JCO.22.01533.
     PubMed     Abstract available
     
     
     July 2022
142. JOHANSSON A, Dar H, van 't Veer LJ, Tobin NP, et al
     Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
     J Clin Oncol. 2022 Jul 21:JCO2102844. doi: 10.1200/JCO.21.02844.
     PubMed     Abstract available
     
     
     
143. RUGO HS, Umanzor GA, Barrios FJ, Vasallo RH, et al
     Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
     J Clin Oncol. 2022 Jul 20:JCO2102953. doi: 10.1200/JCO.21.02953.
     PubMed     Abstract available
     
     
     
144. ULAS KAHYA B, Sutcuoglu O, Yazici O, Ozdemir N, et al
     Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
     J Clin Oncol. 2022 Jul 12:JCO2200404. doi: 10.1200/JCO.22.00404.
     PubMed    
     
     
     
145. SORAN A, Aytac O, Ozbas S
     Locoregional Therapy for Intact Primary Tumor in De Novo Stage IV Breast Cancer.
     J Clin Oncol. 2022 Jul 12:JCO2200802. doi: 10.1200/JCO.22.00802.
     PubMed    
     
     
     
146. LU Y, Meng D, Hui B, Yuan W, et al
     The Deep Inspiration Breath-Hold Technique May Be a Win-Win Option for the Treatment of Patients in Node-Positive Early Left-Sided Breast Cancer.
     J Clin Oncol. 2022 Jul 5:JCO2200931. doi: 10.1200/JCO.22.00931.
     PubMed    
     
     
     June 2022
147. COBAIN EF, Hayes DF
     Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
     J Clin Oncol. 2022 Jun 29:JCO2200702. doi: 10.1200/JCO.22.00702.
     PubMed    
     
     
     
148. HUOBER J, Barrios CH, Niikura N, Jarzab M, et al
     Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
     J Clin Oncol. 2022 Jun 28:JCO2102772. doi: 10.1200/JCO.21.02772.
     PubMed     Abstract available
     
     
     
149. HENRY NL, Somerfield MR, Dayao Z, Elias A, et al
     Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
     J Clin Oncol. 2022 Jun 27:JCO2201063. doi: 10.1200/JCO.22.01063.
     PubMed     Abstract available
     
     
     
150. CHEN YJ, Yeh MH, Wei JC
     Considerations of Subgroup Classification When Analyzing Risk of Developing Cardiometabolic Risk Factors in Patients With Breast Cancer.
     J Clin Oncol. 2022 Jun 16:JCO2200416. doi: 10.1200/JCO.22.00416.
     PubMed    
     
     
     
151. PHILLIPS KA, Friedlander ML
     Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
     J Clin Oncol. 2022;40:1850-1852.
     PubMed    
     
     
     
152. STEENBEEK MP, van Bommel MHD, Bulten J, Hulsmann JA, et al
     Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
     J Clin Oncol. 2022;40:1879-1891.
     PubMed     Abstract available
     
     
     
153. REDING KW, Cheng RK, Barac A, Vasbinder A, et al
     Toward a Better Understanding of the Differential Impact of Heart Failure Phenotypes After Breast Cancer.
     J Clin Oncol. 2022 Jun 10:JCO2200111. doi: 10.1200/JCO.22.00111.
     PubMed    
     
     
     
154. MITTENDORF EA, King TA, Tolaney SM
     Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer.
     J Clin Oncol. 2022 Jun 8:JCO2200173. doi: 10.1200/JCO.22.00173.
     PubMed    
     
     
     
155. CESCON DW, Kalinsky K, DeMichele AM
     Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?
     J Clin Oncol. 2022 Jun 4:JCO2201026. doi: 10.1200/JCO.22.01026.
     PubMed    
     
     
     
156. LIPSYC-SHARF M, de Bruin EC, Santos K, McEwen R, et al
     Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
     J Clin Oncol. 2022 Jun 4:JCO2200908. doi: 10.1200/JCO.22.00908.
     PubMed     Abstract available
     
     
     
157. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
     Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
     J Clin Oncol. 2022;40:1763-1771.
     PubMed     Abstract available
     
     
     
158. ZACHARAKIS N, Huq LM, Seitter SJ, Kim SP, et al
     Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
     J Clin Oncol. 2022;40:1741-1754.
     PubMed     Abstract available
     
     
     May 2022
159. GIORDANO SH, Franzoi MAB, Temin S, Anders CK, et al
     Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
     J Clin Oncol. 2022 May 31:JCO2200519. doi: 10.1200/JCO.22.00519.
     PubMed     Abstract available
     
     
     
160. RAMAKRISHNA N, Anders CK, Lin NU, Morikawa A, et al
     Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
     J Clin Oncol. 2022 May 31:JCO2200520. doi: 10.1200/JCO.22.00520.
     PubMed     Abstract available
     
     
     
161. BACHELOT T, Cottu P, Chabaud S, Dalenc F, et al
     Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
     J Clin Oncol. 2022 May 23:JCO2102179. doi: 10.1200/JCO.21.02179.
     PubMed     Abstract available
     
     
     
162. VAN GEEL JJL, Boers J, Elias SG, Glaudemans AWJM, et al
     Clinical Validity of 16alpha-[(18)F]Fluoro-17beta-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
     J Clin Oncol. 2022 May 18:JCO2200400. doi: 10.1200/JCO.22.00400.
     PubMed     Abstract available
     
     
     
163. BIDARD FC, Kaklamani VG, Neven P, Streich G, et al
     Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
     J Clin Oncol. 2022 May 18:JCO2200338. doi: 10.1200/JCO.22.00338.
     PubMed     Abstract available
     
     
     
164. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
     Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
     J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
     PubMed    
     
     
     
165. LIEBERMAN S, Goldvaser H, Levy-Lahad E
     Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers.
     J Clin Oncol. 2022;40:1590-1594.
     PubMed    
     
     
     
166. DAMODARAN S, Zhao F, Deming DA, Mitchell EP, et al
     Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
     J Clin Oncol. 2022;40:1552-1561.
     PubMed     Abstract available
     
     
     
167. LI S, Silvestri V, Leslie G, Rebbeck TR, et al
     Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
     J Clin Oncol. 2022;40:1529-1541.
     PubMed     Abstract available
     
     
     
168. SINGLETON AC, Raeside R, Hyun KK, Partridge SR, et al
     Electronic Health Interventions for Patients With Breast Cancer: Systematic Review and Meta-Analyses.
     J Clin Oncol. 2022 May 2:JCO2101171. doi: 10.1200/JCO.21.01171.
     PubMed     Abstract available
     
     
     April 2022
169. JIN Z, Zhang S, Zhang L, Chen Q, et al
     Artificial Intelligence Risk Model (Mirai) Delivers Robust Generalization and Outperforms Tyrer-Cuzick Guidelines in Breast Cancer Screening.
     J Clin Oncol. 2022 Apr 22:JCO2102908. doi: 10.1200/JCO.21.02908.
     PubMed    
     
     
     
170. ERIKSSON M, Conant EF, Kontos D, Hall P, et al
     Risk Assessment in Population-Based Breast Cancer Screening.
     J Clin Oncol. 2022 Apr 22:JCO2102827. doi: 10.1200/JCO.21.02827.
     PubMed    
     
     
     
171. DI MEGLIO A, Havas J, Gbenou AS, Martin E, et al
     Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.
     J Clin Oncol. 2022 Apr 21:JCO2100277. doi: 10.1200/JCO.21.00277.
     PubMed     Abstract available
     
     
     
172. VLIEK SB, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum AGJ, et al
     Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
     J Clin Oncol. 2022 Apr 20:JCO2100311. doi: 10.1200/JCO.21.00311.
     PubMed     Abstract available
     
     
     
173. LOPES CARDOZO JMN, Drukker CA, Rutgers EJT, Schmidt MK, et al
     Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.
     J Clin Oncol. 2022;40:1335-1345.
     PubMed     Abstract available
     
     
     
174. BEAVIS PA, Derrick EB, Loi S
     Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer.
     J Clin Oncol. 2022 Apr 19:JCO2200284. doi: 10.1200/JCO.22.00284.
     PubMed    
     
     
     
175. BRAUER ER, Ganz PA
     Moving the Translational Needle in Breast Cancer Survivorship: Connecting Intervention Research to Clinical Practice.
     J Clin Oncol. 2022 Apr 19:JCO2200174. doi: 10.1200/JCO.22.00174.
     PubMed    
     
     
     
176. ANDRE F, Ismaila N, Allison KH, Barlow WE, et al
     Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
     J Clin Oncol. 2022 Apr 19:JCO2200069. doi: 10.1200/JCO.22.00069.
     PubMed     Abstract available
     
     
     
177. ASAZUMA K, Shimomura A, Shimizu C
     Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
     J Clin Oncol. 2022 Apr 14:JCO2200135. doi: 10.1200/JCO.22.00135.
     PubMed    
     
     
     
178. KORDE LA, Somerfield MR, Hershman DL
     Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
     J Clin Oncol. 2022 Apr 13:JCO2200503. doi: 10.1200/JCO.22.00503.
     PubMed     Abstract available
     
     
     
179. DOWSETT M
     Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer.
     J Clin Oncol. 2022 Apr 12:JCO2200214. doi: 10.1200/JCO.22.00214.
     PubMed    
     
     
     
180. NITZ UA, Gluz O, Kummel S, Christgen M, et al
     Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
     J Clin Oncol. 2022 Apr 11:JCO2102759. doi: 10.1200/JCO.21.02759.
     PubMed     Abstract available
     
     
     
181. THORSEN LBJ, Overgaard J, Matthiessen LW, Berg M, et al
     Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study.
     J Clin Oncol. 2022 Apr 8:JCO2200044. doi: 10.1200/JCO.22.00044.
     PubMed     Abstract available
     
     
     
182. GREENLEE H, Iribarren C, Rana JS, Cheng R, et al
     Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.
     J Clin Oncol. 2022 Apr 6:JCO2101736. doi: 10.1200/JCO.21.01736.
     PubMed     Abstract available
     
     
     March 2022
183. NOZAWA K, Hattori M, Yoshimura A, Iwata H, et al
     Clinical Utility of Precision Medicine in Early Breast Cancer: What Is the Optimal Framework to Develop Precision Medicine?
     J Clin Oncol. 2022 Mar 31:JCO2200153. doi: 10.1200/JCO.22.00153.
     PubMed    
     
     
     
184. DE JONG VMT, Wang Y, Ter Hoeve ND, Opdam M, et al
     Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
     J Clin Oncol. 2022 Mar 30:JCO2101536. doi: 10.1200/JCO.21.01536.
     PubMed     Abstract available
     
     
     
185. QIN B, Kim K, Goldman N, Rundle AG, et al
     Multilevel Factors for Adiposity Change in a Population-Based Prospective Study of Black Breast Cancer Survivors.
     J Clin Oncol. 2022 Mar 25:JCO2102973. doi: 10.1200/JCO.21.02973.
     PubMed     Abstract available
     
     
     
186. VAZ-LUIS I, Di Meglio A, Havas J, El-Mouhebb M, et al
     Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.
     J Clin Oncol. 2022 Mar 15:JCO2101958. doi: 10.1200/JCO.21.01958.
     PubMed     Abstract available
     
     
     
187. SALERNO EA, Culakova E, Heckler CE, Janelsins MC, et al
     Reply to S. Ning et al.
     J Clin Oncol. 2022;40:916-918.
     PubMed    
     
     
     
188. DELAHUNTY R, Nguyen L, Craig S, Creighton B, et al
     TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
     J Clin Oncol. 2022 Mar 9:JCO2102108. doi: 10.1200/JCO.21.02108.
     PubMed     Abstract available
     
     
     
189. JATOI I
     Ductal Carcinoma In Situ and Breast Cancer Overdiagnosis.
     J Clin Oncol. 2022 Mar 4:JCO2102802. doi: 10.1200/JCO.21.02802.
     PubMed    
     
     
     
190. GRIMM LJ, Plichta JK, Hwang ES
     More Than Incremental: Harnessing Machine Learning to Predict Breast Cancer Risk.
     J Clin Oncol. 2022 Mar 4:JCO2102733. doi: 10.1200/JCO.21.02733.
     PubMed    
     
     
     
191. THOMAS A, Parsons HA, Smith KL
     Late Recurrence Following Early Breast Cancer.
     J Clin Oncol. 2022 Mar 3:JCO2200167. doi: 10.1200/JCO.22.00167.
     PubMed     Abstract available
     
     
     February 2022
192. JAHAN N, Cathcart-Rake EJ, Ruddy KJ
     Late Breast Cancer Survivorship: Side Effects and Care Recommendations.
     J Clin Oncol. 2022 Feb 28:JCO2200049. doi: 10.1200/JCO.22.00049.
     PubMed     Abstract available
     
     
     
193. HICKS D, O'Regan RM
     Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.
     J Clin Oncol. 2022 Feb 24:JCO2102850. doi: 10.1200/JCO.21.02850.
     PubMed     Abstract available
     
     
     
194. KEMP EB, Geerse OP, Knowles R, Woodman R, et al
     Mapping Systematic Reviews of Breast Cancer Survivorship Interventions: A Network Analysis.
     J Clin Oncol. 2022 Feb 16:JCO2102015. doi: 10.1200/JCO.21.02015.
     PubMed     Abstract available
     
     
     
195. PEDERSEN RN, Mellemkjaer L, Ejlertsen B, Norgaard M, et al
     Mortality After Late Breast Cancer Recurrence in Denmark.
     J Clin Oncol. 2022 Feb 16:JCO2102062. doi: 10.1200/JCO.21.02062.
     PubMed     Abstract available
     
     
     
196. ANG BH, Ho WK, Wijaya E, Kwan PY, et al
     Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
     J Clin Oncol. 2022 Feb 10:JCO2101647. doi: 10.1200/JCO.21.01647.
     PubMed     Abstract available
     
     
     
197. ANDERSON DN, Port ER
     Surgery No More? Managing the Primary Tumor in Stage IV Breast Cancer.
     J Clin Oncol. 2022 Feb 4:JCO2102706. doi: 10.1200/JCO.21.02706.
     PubMed     Abstract available
     
     
     
198. PARAMANANDAM VS, Dylke E, Clark GM, Daptardar AA, et al
     Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled Trial.
     J Clin Oncol. 2022 Feb 2:JCO2102567. doi: 10.1200/JCO.21.02567.
     PubMed     Abstract available
     
     
     
199. PFOB A, Sidey-Gibbons C, Rauch G, Thomas B, et al
     Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
     J Clin Oncol. 2022 Feb 2:JCO2102439. doi: 10.1200/JCO.21.02439.
     PubMed     Abstract available
     
     
     
200. CARLOS RC, Obeng-Gyasi S, Cole SW, Zebrack BJ, et al
     Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach.
     J Clin Oncol. 2022 Feb 2:JCO2102004. doi: 10.1200/JCO.21.02004.
     PubMed    
     
     
     
201. BARTON DL, Pugh SL, Ganz PA, Plaxe SC, et al
     Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.
     J Clin Oncol. 2022;40:324-334.
     PubMed     Abstract available
     
     
     January 2022
202. ROYCE M, Osgood C, Mulkey F, Bloomquist E, et al
     FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
     J Clin Oncol. 2022 Jan 27:JCO2102742. doi: 10.1200/JCO.21.02742.
     PubMed     Abstract available
     
     
     
203. RAFN BS, Christensen J, Larsen A, Bloomquist K, et al
     Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis.
     J Clin Oncol. 2022 Jan 25:JCO2101681. doi: 10.1200/JCO.21.01681.
     PubMed     Abstract available
     
     
     
204. DI MEGLIO A, Havas J, Soldato D, Presti D, et al
     Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.
     J Clin Oncol. 2022 Jan 21:JCO2101252. doi: 10.1200/JCO.21.01252.
     PubMed     Abstract available
     
     
     
205. NING S, Qiao K, Pan L
     Physical Activity Patterns and Cognitive Function in Patients With Breast Cancer.
     J Clin Oncol. 2022 Jan 21:JCO2102073. doi: 10.1200/JCO.21.02073.
     PubMed    
     
     
     
206. WRIGHT JL, Rahbar H, Obeng-Gyasi S, Carlos R, et al
     Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.
     J Clin Oncol. 2022;40:225-230.
     PubMed    
     
     
     
207. SHEPHERD JH, Ballman K, Polley MC, Campbell JD, et al
     CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
     J Clin Oncol. 2022 Jan 19:JCO2101506. doi: 10.1200/JCO.21.01506.
     PubMed     Abstract available
     
     
     
208. EISEN A, Somerfield MR, Accordino MK, Blanchette PS, et al
     Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
     J Clin Oncol. 2022 Jan 18:JCO2102647. doi: 10.1200/JCO.21.02647.
     PubMed     Abstract available
     
     
     
209. KWAN ML, Cheng RK, Iribarren C, Neugebauer R, et al
     Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.
     J Clin Oncol. 2022 Jan 13:JCO2101738. doi: 10.1200/JCO.21.01738.
     PubMed     Abstract available
     
     
     
210. JOENSUU H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, et al
     Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
     J Clin Oncol. 2022 Jan 12:JCO2102054. doi: 10.1200/JCO.21.02054.
     PubMed     Abstract available
     
     
     
211. KHAN SA, Zhao F, Goldstein LJ, Cella D, et al
     Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
     J Clin Oncol. 2022 Jan 7:JCO2102006. doi: 10.1200/JCO.21.02006.
     PubMed     Abstract available
     
     
     
212. MAYER EL, Fesl C, Hlauschek D, Garcia-Estevez L, et al
     Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/AB
     J Clin Oncol. 2022 Jan 7:JCO2101918. doi: 10.1200/JCO.21.01918.
     PubMed     Abstract available
     
     
     December 2021
213. SCHNEIDER BP, Jiang G, Ballinger TJ, Shen F, et al
     BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
     J Clin Oncol. 2021 Dec 15:JCO2101657. doi: 10.1200/JCO.21.01657.
     PubMed     Abstract available
     
     
     
214. KROP IE, Im SA, Barrios C, Bonnefoi H, et al
     Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
     J Clin Oncol. 2021 Dec 10:JCO2100896. doi: 10.1200/JCO.21.00896.
     PubMed     Abstract available
     
     
     
215. YADAV S, Hu C, Nathanson KL, Weitzel JN, et al
     Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
     J Clin Oncol. 2021;39:3918-3926.
     PubMed     Abstract available
     
     
     
216. GIORDANO SH, Freedman RA, Somerfield MR
     Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
     J Clin Oncol. 2021 Dec 8:JCO2102677. doi: 10.1200/JCO.21.02677.
     PubMed     Abstract available
     
     
     
217. GNANT M, Dueck AC, Frantal S, Martin M, et al
     Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
     J Clin Oncol. 2021 Dec 7:JCO2102554. doi: 10.1200/JCO.21.02554.
     PubMed     Abstract available
     
     
     November 2021
218. YALA A, Mikhael PG, Strand F, Lin G, et al
     Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model.
     J Clin Oncol. 2021 Nov 12:JCO2101337. doi: 10.1200/JCO.21.01337.
     PubMed     Abstract available
     
     
     
219. WARREN LEG, Bellon JR
     Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?
     J Clin Oncol. 2021;39:3535-3540.
     PubMed     Abstract available
     
     
     
220. MCCORMICK B, Winter KA, Woodward W, Kuerer HM, et al
     Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
     J Clin Oncol. 2021;39:3574-3582.
     PubMed     Abstract available
     
     
     October 2021
221. BORGES VF
     Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
     J Clin Oncol. 2021 Oct 28:JCO2101910. doi: 10.1200/JCO.21.01910.
     PubMed     Abstract available
     
     
     
222. ADEMUYIWA FO, Salyer P, Tao Y, Luo J, et al
     Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.
     J Clin Oncol. 2021 Oct 18:JCO2101426. doi: 10.1200/JCO.21.01426.
     PubMed     Abstract available
     
     
     
223. PALMER JR, Zirpoli G, Bertrand KA, Battaglia T, et al
     A Validated Risk Prediction Model for Breast Cancer in US Black Women.
     J Clin Oncol. 2021 Oct 8:JCO2101236. doi: 10.1200/JCO.21.01236.
     PubMed     Abstract available
     
     
     September 2021
224. DE RUITER MB, Reneman L, Kieffer JM, Oldenburg HSA, et al
     Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.
     J Clin Oncol. 2021 Sep 30:JCO2100627. doi: 10.1200/JCO.21.00627.
     PubMed     Abstract available
     
     
     
225. JAYASEKERA J, Sparano JA, O'Neill S, Chandler Y, et al
     Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions.
     J Clin Oncol. 2021;39:2893-2902.
     PubMed     Abstract available
     
     
     July 2021
226. COBLEIGH MA, Anderson SJ, Siziopikou KP, Arthur DW, et al
     Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
     J Clin Oncol. 2021;39:2367-2374.
     PubMed     Abstract available
     
     
     June 2021
227. TURAN V, Lambertini M, Lee DY, Wang E, et al
     Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.
     J Clin Oncol. 2021;39:2016-2024.
     PubMed     Abstract available
     
     
     
228. ERIKSSON M, Eklund M, Borgquist S, Hellgren R, et al
     Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
     J Clin Oncol. 2021;39:1899-1908.
     PubMed     Abstract available
     
     
     May 2021
229. PRAT A, Chaudhury A, Solovieff N, Pare L, et al
     Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
     J Clin Oncol. 2021;39:1458-1467.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.